Arista Networks Soars as Traders Buy Calls
Arista Networks jumps 8% on heavy call option buying, fueled by AI data center growth and bullish analyst outlooks.
Already have an account? Sign in.
Arista Networks jumps 8% on heavy call option buying, fueled by AI data center growth and bullish analyst outlooks.
Context Therapeutics reported positive Phase 1 data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer, showing a 29% response rate and good safety, but the stock fell due to small trial size.
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
Bernstein says Fiserv’s appointment of Takis Georgakopoulos as CEO has a “bad look,” coming just weeks after Investor Day while the stock is at 10-year lows.